GlaxoSmithKline says it has updated the labeling of its diabetes pill Avandia to include safety restrictions ordered by federal health authorities because of the drug's links to heart attack.
Full story

GlaxoSmithKline will record a legal charge of 2.2 billion pounds ($3.4 billion) for the fourth quarter, effectively wiping out its profit, as it settles further claims related to Avandia and sales practices.
Full story

U.S. government health regulators will allow GlaxoSmithKline to continue selling a controversial diabetes pill but will restrict access to the once-blockbuster drug because of heart attack risks.
Full story

After a long-running controversy about Avandia's heart attack risk, the FDA put such tight restrictions on it that sales in this country are expected to plunge to nearly zero. Meanwhile, regulators in Europe say Avandia will no longer be available at all. NBC's Brian Williams reports.

Related Photos

MIAMI - JULY 14: A bottle and pills of the diabetes drug, Avandia are seen on July 14, 2010 in Miami, Florida. European and American drug regulators announced September 23, 2010, that sales of GlaxoSmithKline PLC's diabetes drug, Avandia, will be heavily restricted in the United States and complet